Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.
6400 Westwind Way
Crestwood, KY 40014
Founded in 2009
Apellis Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board
Jul 15 15
Apellis Pharmaceuticals, Inc. announced the formation of a Scientific Advisory Board. Carl Atkinson, PhD. Assistant Professor Microbiology & Immunology, Medical University of South Carolina, USA. Robert A. Brodsky, MD. Director, Division of Hematology, Professor of Medicine and Oncology, Johns Hopkins Hospital, USA. Gabriel J. Coscas, MD. Professor and Chairman of Ophthalmology, University of Paris XII, France. Peter Hillmen, MD, PhD. Professor of Experimental Hematology, Leeds Institute of Cancer & Pathology, UK. Claudia Kemper, PhD. Faculty, King's College, UK. Susan M. Lea, PhD. Chair and Professor of Microbiology, Co-Director, Oxford Martin Programme on Vaccines, Sir William Dunn School of Pathology, UK. Toby Maher, MD, PhD. Clinician Scientist, Pulmonologist and Honorary Senior Lecturer, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, UK. Philip J. Rosenfeld, MD, PhD. Professor of Ophthalmology, Bascom Palmer Eye Institute, USA. Johanna M. Seddon, MD, ScM. Professor of Ophthalmology, Tufts University School of Medicine, Boston, USA. Dave Singh, MD. Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, UK. Jason S. Slakter, MD.Vitreous Retina Macular Consultants of New York and Clinical Professor of Ophthalmology, New York University School of Medicine, USA. Janet S. Sunness, MD. Medical Director of Richard E. Hoover Low Vision Rehabilitation Services, Greater Baltimore Medical Center, USA. Marsha Wills-Karp, PhD. Professor, Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, USA. Mike Yeadon, PhD. President and CEO, Ziarco, UK.
Apellis Pharmaceuticals, Inc. Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
Feb 10 15
Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2 in patients suffering from age-related macular degeneration (AMD). The trial, labeled ASAP II, will focus on establishing safety of intravitreal injections of APL-2 and will be conducted in patients afflicted with wet AMD at multiple sites in the United States and Australia. The company plans to follow ASAP II with a larger Phase II trial in patients with geographic atrophy (the advanced stage of dry AMD) in the late spring of 2015.